The relationship between c-erbB-2 gene expression (assessed immunohistochemically), S-phase fraction (SPF) and prognosis has been analysed in 172 women with primary breast cancer. c-erbB-2 staining was independent of age, tumour size, number of nodes involved, tumour grade and DNA ploidy, but was more common in oestrogen receptor (ER) negative tumours (P = 0.02) and progesterone receptor (PgR) negative tumours (P = 0.03). A weak correlation between c-erbB-2 staining and SPF was observed (r = 0.18). Amongst women with node negative disease, SPF was significantly related to relapse free survival (RFS, P = 0.04) while c-erbB-2 staining was not (P = 0.2). In contrast, both SPF (P = 0.002) and c-erbB-2 staining (P = 0.016) provided significant prognostic information on RFS for women with node positive disease. Multivariate analysis showed that c-erbB-2 staining and SPF gave independent information on RFS for women with node positive disease.
Amplification of the c-erbB-2 proto-oncogene occurs in 10-33% of human breast cancers (Slamon et al., 1987; Venter et al., 1987; Ali et al., 1988) . This gene codes for a 185-190 kilodalton transmembrane glycoprotein. The cerbB-2 oncogene product can be detected immunohistochemically using formalin-fixed or frozen tissue (Venter et al., 1987; Barnes et al., 1988; Gusterson et al., 1988; van de Vijver et al., 1988; Wright et al., 1989; Tandon et al., 1989; Lovekin et al., 1989; Paik et al., 1989; Dolan et al., 1989) . Over-expression of the c-erbB-2 oncoprotein has been reported to be associated with a shorter relapse free survival (RFS) and survival for breast cancer patients, particularly those with axillary node positive disease (Venter et al., 1987; Barnes et al., 1988; Gusterson et al., 1988; van de Vijver et al., 1988; Wright et al., 1989; Tandon et al., 1989; Lovekin et al., 1989; Paik et al., 1989; Dolan et al., 1989; Slamon et al., 1989; Borg et al., 1989) . As the c-erbB-2 oncogene product has a structure highly homologous to that of the epidermal growth factor receptor Yamamoto et al., 1986) , it has been postulated that over-expression of this protein might be associated with faster tumour proliferation. In this study we have examined the relationship between c-erbB-2 expression and tumour proliferation, measured by estimating the proportion of cells in the S-phase of the cell cycle using DNA flow cytometry. In previous studies, we and others have shown high S-phase fraction (SPF) to be an indicator of poor prognosis both in node negative and node positive breast cancer (O'Reilly et al., 1990a; O'Reilly et al., 1990b) . By examining both c-erbB-2 expression and SPF we have been able to assess whether these two features of the tumour give independent prognostic information. (Camplejohn et al., 1989) .
Methods

Immunohistochemistry
Staining was assessed on 3 lm sections cut from formalinfixed, paraffin-embedded tissue as described previously (Barnes et al., 1988) . Briefly, sections were incubated overnight at 4°C with a 3 1tg ml-' solution of affinity purified polyclonal antibody 21N (kindly supplied by Dr W.J. Gullick, Hammersmith Hospital) raised in rabbits to the predicted amino acid sequence from residues 1243-1255 of c-erbB-2 . Sections were then treated with biotinylated swine anti-rabbit immunoglobulin at 1:500 dilution followed by avidin-biotin peroxidase complex for 30 min. Peroxidase activity was demonstrated using diamino-benzidine solution and the nuclei were counterstained with haematoxylin. Staining was scored by assessing the proportion of cells staining (0%, 1-20%, 21-80%, 81-100%) and the intensity of staining (weak (+), moderate (+ +) or strong (++ + )). All cases were reviewed by two observers.
Statistical analysis
Relationships between variables were examined using the Chi squared test, the Mann-Whitney non-parametric test and the Pearson correlation coefficient. Relapse free survival and survival curves were calculated using the method of Kaplan and Meier (Peto et al., 1977) and differences between curves were analysed by the logrank test. Multivariate analysis was performed using the Cox proportional hazards model (Cox, 1972) .
Results Thirty-nine of the 172 tumours (23%) showed some degree of tumour cell membrane staining for the c-erbB-2 product. There was a close correlation between intensity of staining and percentage of cells stained (r = 0.92). Twenty-eight tumours (16%) had moderate or strong staining of more than 20% of cells and were regarded as c-erbB-2 positive. The remaining 144 tumours, which exhibited either no staining or weak staining, were classified as c-erbB-2 negative.
The relationship between c-erbB-2 immunostaining and other tumour characteristics is shown in Table I . c-erbB-2 positive tumours were significantly more likely to be ER negative (P = 0.02) and PgR negative (P = 0.03) than c-erbB-2 negative tumours. No association was observed between c-erbB-2 staining and tumour size, grade, nodal status, or DNA ploidy.
S-phase fraction (SPF) could be measured for 153/172 (87%) tumours, with a median value of 8% (range 1.1-35%). There was a significant association between cerbB-2 staining and an SPF above the median using Chisquared analysis (P = 0.003). In addition, the median SPF of c-erbB-2 positive tumours was significantly higher then the median SPF of c-erbB-2 negative tumours (10.5 vs 7.9, P = 0.02). However, the correlation coefficient between cerbB-2 staining and SPF was only 0.18 showing this to be a weak association.
There was no significant difference in relapse free survival (RFS) between patients with c-erbB-2 negative tumours and those with c-erbB-2 positive tumours (P = 0.2). While there was a trend for patients with c-erbB-2 positive tumours to have a shorter survival, this did not achieve statistical significance (P = 0.08). The influence of c-erbB-2 on outcome was then examined within subgroups defined by nodal status. c-erbB-2 staining did not influence either RFS (P = 0.2) or survival (P = 0.8) for patients with node negative breast cancer. However, patients with node positive disease whose tumours were also c-erbB-2 positive had both a shorter RFS ( Figure 1 ) and survival ( Figure 2 ) than those with c-erbB-2 negative tumours. In contrast, high SPF was an indicator of poor prognosis in both node negative (RFS P = 0.04; S P = 0.05) and node positive (RFS P = 0.002; S P = 0.02) disease.
Multivariate analysis was performed to assess the independence of the prognostic information given by c-erbB-2 staining and SPF in node positive breast cancer. This showed that the number of positive axillary nodes was the most powerful predictor of both RFS (P = 0.001) and survival (P = 0.01). However, both c-erbB-2 staining (P = 0.02) and SPF (P = 0.03) were significant independent prognostic variables for RFS, but not for survival.
Discussion
There have been a number of conflicting reports of the relationship between c-erbB-2 amplification or expression and other pathological features of human breast cancer (Slamon et al., 1987; Venter et al., 1987; Ali et al., 1988; Barnes et al., 1988; Gusterson et al., 1988; van de Vijver et al., 1988; Wright et al., 1989; Tandon et al., 1989; Lovekin et al., 1989; Paik et al., 1989; Dolan et al., 1989; Slamon et al., 1989; Borg et al., 1989; Zhou et al., 1987 ). An association has been reported between c-erbB-2 expression and large tumour size in only two studies (van de Vijver et al., 1988; Borg et al., 1989) . A significant association between c-erbB-2 expression and poorly differentiated tumours has been demonstrated in some studies (Barnes et al., 1988; Wright et al., 1989; Lovekin et al., 1989) but not in others (van de Vijver et al., 1988; Zhou et al., 1987) . Similarly, the inverse relationship noted in some studies between c-erbB-2 expression and steroid receptor status (Wright et al., 1989; Tandon et al., 1989; Lovekin et al., 1989; Zhou et al., 1987) has not been universally found (Barnes et al., 1988; Paik et al., 1989) other report analysing the relationship between c-erbB-2 expression and DNA ploidy measured by flow cytometry (Borg et al., 1989) found no significant association. In the current analysis, steroid receptor status was the only one of these factors significantly associated with c-erbB-2 status.
As the c-erbB-2 oncogene product has a structure highly homologous to that of the epidermal growth factor receptor Yamamoto et al., 1986) , it has been postulated that over-expression of this protein might be associated with faster tumour proliferation. In this study, a statistically significant association was observed between cerbB-2 expression and high SPF using both Chi-squared and non-parametric analysis. However, these tests do not estimate the proportion of variability in one factor attributable to its relationship with the other. Such an estimate is, however, obtained by squaring the correlation coefficient. Our results, with a correlation coefficient of 0.18, suggest that less than 5% of the variability in SPF is due to its association with c-erbB-2. Borg et al. (1989) , in the only other report examining the relationship between SPF and c-erbB-2 expression in infiltrating tumours, found a highly significant (P=0.0001) association between c-erbB-2 and high SPF using Chisquared analysis, but did not report a correlation coefficient. Their report also found c-erbB-2 to be significantly associated with nodal status, tumour size, clinical stage, ER status and PgR status in addition to SPF.
The relationship between the c-erbB-2 oncogene and prognosis for patients with breast cancer has now been examined in a number of studies. These have related both gene amplification (Slamon et al., 1987; Zhou et al., 1987; Ali et al., 1988; Slamon et al., 1989) and over-expression of the oncogene product (Venter et al., 1987; Barnes et al., 1988; Gusterson et al., 1988; van de Vijver et al., 1988; Wright et al., 1989; Tandon et al., 1989; Lovekin et al., 1989; Paik et al., 1989; Dolan et al., 1989; Slamon et al., 1989; Borg et al., 1989) to clinical outcome. While some studies have not found an association between c-erbB-2 and poor prognosis (Barnes et al., 1988; van de Vijver et al., 1988; Gusterson et al., 1988) , recent large studies, each including more than 500 patients, have demonstrated a correlation between c-erbB-2 and both shorter relapse free survival and survival (Slamon et al., 1989; Tandon et al., 1989; Lovekin et al., 1989) . Two studies have reported that the prognostic significance of cerbB-2 is confined to patients with node positive breast cancer (Slamon et al., 1989; Tandon et al., 1989) . Our report confirms the association between c-erbB-2 staining and poor prognosis for patients with node positive disease. In addition, multivariate analysis shows that, while the number of axillary nodes containing tumour deposits is the most powerful predictor of relapse free survival, c-erbB-2 expression and SPF give additional independent significant prognostic information.
The mechanism of action by which expression of the cerbB-2 oncoprotein leads to a poor prognosis remain uncertain. We found no significant relationship between c-erbB-2 expression and tumour burden, as measured by tumour size or the number of nodes involved. One possibility would be that c-erbB-2 expression is associated with resistance to chemotherapy or endocrine therapy. In this study, the association of c-erbB-2 expression with both shorter RFS and survival does not, however, support this hypothesis. Our results, albeit on a relatively small number of patients, also suggest that c-erbB-2 expression contributes little to the proliferative activity of the primary tumour. Further studies are required to assess the relationship between c-erbB-2 and proliferative activity in metastases.
